Sofinnova leads €35.5m capital increase for Inventiva

The VC firm drew capital from Sofinnova Crossover Fund I, which held a final close on €275m in April 2018, surpassing its €250m target.

The fund was launched with the strategy of targeting later-stage companies and making investments in both private and public markets.

Inventiva will use the fresh capital to advance its clinical programmes, in particular allowing the company's lead compound, lanifbranor, to advance towards phase-III trials.

Company
Inventiva was founded in October 2011 and has been listed on Euronext Paris since February 2017. It is a biopharmaceutical company specialising in the development of treatments for fibrotic and orphan diseases, such as non-alcoholic steato hepatitis (NASH), systemic scleroderma (SSC) and mucopolysaccharidosis (MPS). The company employed 107 people as of December 2017 and generated a loss of €20.4m for the year.

People
Sofinnova Partners – Jacques Theurillat (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• PIPEs
• France
• Healthcare
• Venture
• Sofinnova Partners
• France